Bibliography
[1] Cystic fibrosis mutation database. Hospital for Sick Children, Toronto. www.genet.sickkids.on.ca. Accessed September 29, 2018
[2] David A Stoltz, David K Meyerholz, Michael J Welsh, Origins of cystic fibrosis lung disease N Engl J Med 2015 Jan 22;372(4):351-62. doi: 10.1056/NEJMra1300109.
[3] Bouhuys A, van Lennep H. Effect of body posture on gas distribution in the lungs. J Appl Physiol. 1962 Jan;17:38-42. doi: 10.1152/jappl.1962.17.1.38.
[4] Sivagurunathan Sutharsan, Edward F McKone, Damian G Downey, Jamie Duckers, Gordon MacGregor, Elizabeth Tullis, Eva Van Braeckel, Claire E. Wainwright, Danie Watson, Neil Ahluwalia et al. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Lancet Respir Med. 2022 Mar;10(3):267-277. doi: 10.1016/S2213-2600(21)00454-9.
[5] Simon Y Graeber, Diane M Renz, Mirjam Stahl, Sophia T Pallenberg, Olaf Sommerburg, Lutz Naehrlich, Julian Berges, Martha Dohna, Felix C Ringshausen, Felix Doellinger et al. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles. Am J Respir Crit Care Med 2022 May 10. doi: 10.1164/rccm.202201-0219OC.
[6] Paul D Robinson, Philipp Latzin, Sylvia Verbanck, Graham L Hall, Alexander Horsley, Monika Gappa, Cindy Thamrin, Hubertus G M Arets, Paul Aurora, Susanne I Fuchs et al. Consensus statement for inert gas washout measurement using multiple- and single- breath tests. Eur Respir J. 2013 Mar;41(3):507-22. doi: 10.1183/09031936.00069712.
[7] A R Horsley, P M Gustafsson, K A Macleod, C Saunders, A P Greening, D J Porteous, J C Davies, S Cunningham, E W F W Alton, J A Innes. Lung clearance index is a sensitive, repeatable and practicalmeasure of airways disease in adults with cystic fibrosis. Thorax 2008 Feb;63(2):135-40. doi: 10.1136/thx.2007.082628.
[8] Harm A W M Tiddens, Detecting early structural lung damage in cystic fibrosis. Pediatr Pulmonol 2002; 34: 228–231. doi: 10.1002/ppul.10134.
[9] Gustafsson PM, Aurora P, Lindblad A. Evaluation of ventilation maldistribution as an early indicator of lung disease in children with cystic fibrosis. Eur Respir J 2003; 22: 972–979. doi: 10.1183/09031936.03.00049502.
[10] P Aurora, P Gustafsson, A Bush, A Lindblad, C Oliver, C E Wallis, J Stocks. Multiple breath inert gas washout as a measure of ventilation distribution in children with cystic fibrosis. Thorax 2004 Dec;59(12):1068-73. doi: 10.1136/thx.2004.022590.
[11] O’Neill K, Johnston E, Tunney MM, Stephen Rowan, Damian G. Downey,
Jacqueline Rendall, Alastair Reid, Ian Bradbury, J. Stuart Elborn, Judy M. Bradley. Lung clearance index (LCI): a sensitive outcome measure in adults and children with cystic fibrosis (CF). Phys Ther Rev 2014; 19: 57.
[12] Esther Oude Engberink, Felix Ratjen, Stephanie D Davis, George Retsch-Bogart, Reshma Amin, Sanja Stanojevic. Inter-test reproducibility of the lung clearance index measured by multiple breath washout. Eur Respir J. 2017 Oct 5;50(4):1700433. doi: 10.1183/13993003.00433-2017.
[13] K. O’Neill, J. Elborn, E. Johnston, J. Bradley, M. Tunney. Changes in lung clearance index during periods of stability and pulmonary exacerbation. Pediatr Pulmonol 2012; 47: Suppl. 35, 352–353.
[14] O’Neill K, Johnston E, Tunney M, Stuart Elborn J, Bradley J. Lung clearance index (LCI) during and following a pulmonary exacerbation (PEx) in patients with CF. J Cyst Fibros 2012; 11: Suppl. 1, S97.
[15] C M Owens, P Aurora, S Stanojevic, A Bush, A Wade, C Oliver, A Calder, J Price, S B Carr, A Shankar, Janet Stocks; London Cystic Fibrosis Collaboration. Lung clearance index and HRCT are complementary markers of lung abnormalities in young children with CF. Thorax 2011 Jun;66(6):481-8. doi: 10.1136/thx.2010.150375.
[16] Michael D Parkins, Jacqueline C Rendall, J Stuart Elborn. Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest 2012 Feb;141(2):485-493. doi: 10.1378/chest.11-0917
[17] J Michael Collaco, Deanna M Green, Garry R Cutting, Kathleen M Naughton, Peter J Mogayzel Jr. Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes. Am J Respir Crit Care Med. 010 Nov 1;182(9):1137-43. doi: 10.1164/rccm.201001-0057OC.
[18] Claudia L Ordoñez, Noreen R Henig, Nicole Mayer-Hamblett, Frank J Accurso, Jane L Burns, James F Chmiel, Cori L Daines, Ronald L Gibson, Sharon McNamara, George Z Retsch-Bogart et al. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med. 2003 Dec 15; 168(12):1471-5. doi: 10.1164/rccm.200306-731OC.
[19] Don B Sanders, Rachel C L Bittner, Margaret Rosenfeld, Lucas R Hoffman, Gregory J Redding, Christopher H Goss. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med. 2010 Sep 1;182(5):627-32. doi: 10.1164/rccm.200909-1421OC.
[20] Donald R VanDevanter, Mary A O’Riordan, Jeffrey L Blumer, Michael W Konstan. Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. Respir Res. 2010 Oct 6;11(1):137. doi: 10.1186/1465-9921-11-137.
[21] Paul D Robinson, Peter Cooper, Peter Van Asperen, Dominic Fitzgerald, Hiran Selvadurai. Using index of ventilation to assess response to treatment for acute pulmonary exacerbation in children with cystic fibrosis. Pediatr Pulmonol. 2009 Aug;44(8):733-42. doi: 10.1002/ppul.20956.
[23] Eef Vanderhelst, Liesbeth De Meirleir, Daniel Schuermans, Anne Malfroot, Walter Vincken, Sylvia Verbanck. Evidence of an acinar response following treatment for exacerbation in adult patients with cystic fibrosis. Respiration. 2014;87(6):492-8. doi: 10.1159/000360772.
[23] Liam Welsh, Christopher Nesci, Haily Tran, Marisol Tomai, Sarath Ranganathan. Lung clearance index during hospital admission in school-age children with cystic fibrosis. J Cyst Fibros. 2014 Dec;13(6):687-91. doi: 10.1016/j.jcf.2014.05.012.
[24] Sophie Yammine, Anja Bigler, Carmen Casaulta, Florian Singer, Philipp Latzin. Reasons for heterogeneous change in LCI in children with cystic fibrosis after antibiotic treatment. Thorax. 2014 Feb;69(2):183. doi: 10.1136/thoraxjnl-2013-204283.
[25] Nicole Sonneveld, Sanja Stanojevic, Reshma Amin, Paul Aurora, Jane Davies, J. Stuart Elborn, Alex Horsley, Philipp Latzin, Katherine O’Neill, Paul Robinson et al. Lung clearance index in cystic fibrosis subjects treated for pulmonary exacerbations. Eur Respir J. 2015 Oct;46(4):1055-64. doi: 10.1183/09031936.00211914.
[26] Button BM, Wilson C, Dentice R, Cox NS, Middleton A, Tannenbaum E, Bishop J, Cobb R, Burton K, Wood M. Physiotherapy for cystic fibrosis in Australia and New Zealand: A clinical practice guideline. Respirology. 2016 May;21(4):656-67. doi: 10.1111/resp.12764. Epub 2016 Apr 18
[27] Paul D. Robinson, Philipp Latzin, Sylvia Verbanck, Graham L. Hall, Alexander Horsley, Monika Gappa, Cindy Thamrin, Hubertus G M Arets, Paul Aurora, Susanne I Fuchs et al. Consensus statement for inert gas washout measurement using multiple- and single- breath tests European Respiratory Journal 2013 41: 507-522; DOI: 10.1183/09031936.0006971
[28] Pinelopi Anagnostopoulou, Philipp Latzin, Renee Jensen, Mirjam Stahl, Alana Harper, Sophie Yammine, Usemann J, Foong RE, Spycher B, Hall GL et al. Normative data for multiple breath washout outcomes in school-aged Caucasian children. Eur Respir J. 2020 Apr 3;55(4):1901302. doi: 10.1183/13993003.01302-2019.
[29] Philip H Quanjer, Sanja Stanojevic, Tim J Cole, Xaver Baur, Graham L Hall, Bruce H Culver, Paul L Enright, John L Hankinson, Mary S M Ip, Jinping Zheng et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012 Dec;40(6):1324-43. doi: 10.1183/09031936.00080312.
[30] Hatziagorou E, Avramidou V, Kirvassilis F, Tsanakas J. Use of lung clearance index to assess the response to intravenous treatment in cystic fibrosis Use of lung clearance index to assess the response to intravenous treatment in cystic fibrosis. Hippokratia. 2015 Jan-Mar;19(1):47-52.
[31] Jonathan H Rayment, Sanja Stanojevic, Stephanie D Davis, George Retsch-Bogart, Felix Ratjen. Lung clearance index to monitor treatment response in pulmonary exacerbations in preschool children with cystic fibrosis. Thorax. 2018 May;73(5):451-458. doi: 10.1136/thoraxjnl-2017-210979.
[32] Marcus Svedberg, Per M Gustafsson, Paul D Robinson, Monica Rosberg, Anders Lindblad. Variability of lung clearance index in clinically stable cystic fibrosis lung disease in school age children. J Cyst Fibros. 2018 Mar;17(2):236-241. doi: 10.1016/j.jcf.2017.08.004.
[33] Dong K, Huh SM, Lam GY, Jang J, Franciosi AN, Wilcox PG, Bradley S Quon. Pulmonary exacerbation inflammatory phenotypes in adults with cystic fibrosis. J Cyst Fibros. 2022 Dec 24:S1569-1993(22)01433-3. doi: 10.1016/j.jcf.2022.12.013.
Acknowledgements None.
Authors’ contributions MDM, EM and LC conceived the study. MDM and AB wrote the manuscript. MDM ,LC and AF collected data. RC and AGF conceived and directed the work thanks to their knowledge of the subject matter. All authors analyzed and interpreted patients’ data, read and approved the final manuscript.
Funding None
Availability of data and materials The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Ethics approval and consent to participate Local ethics committees approved the study (n° 2819_OPBG_2022). Parental consent was not required because this is a retrospective study and data were anonymized.
Consent for publication Not applicable.
Competing interests The authors declare that they have no competing interests.